Aquyre Biosciences Reaches Major Procedure Milestone During Lung Awareness Month
Pushing the Future of Lung Cancer Diagnostics Forward
“We are thrilled to have quickly reached such a milestone and accelerate the accurate diagnosis of patients,” said Aquyre Biosciences’ CEO Bertrand Le Conte De Poly. “This rapid adoption is testament to the technology and speaks to the future of diagnostics and advanced treatment options. We look forward to being on the forefront of that.”
CelTivity’s ease of use and easy to read imaging has led many top institutions to quickly adopt the system in their biopsy program.
“By using CelTivity, we’ve had over 95% concorded with final pathology. There’d be instances where we would be in a lesion and would see cancer using CelTivity, however traditional ROSE would say they didn’t see anything.” Said Dr. Stephen Kovacs, UPMC Hamot Comprehensive Lung Center, “We’d send the sample to final pathology and they would agree with us, that there was in fact cancer.”
To learn more about Aquyre Biosciences and CelTivity visit www.aquyre.com.
Director of Marketing, Aquyre Bioscience